Belite Bio (BLTE) vs Ligand Pharmaceuticals (LGND)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Belite Bio (BLTE) has outperformed Ligand Pharmaceuticals (LGND) over the past year, gaining 101.7% versus a gain of 60.1%. Belite Bio is the larger company by market cap ($6.29 billion vs $5.85 billion), about 1.1 times the size. On valuation, Ligand Pharmaceuticals trades at a lower forward P/E (24.5x vs 69.1x for Belite Bio).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLTE | LGND |
|---|---|---|
| Share price | $156.08 | $293.26 |
| Market cap | $6.29B | $5.85B |
| 1-day change | +0.30% | -1.24% |
| YTD return | -2.43% | +55.11% |
| 1-year return | +101.65% | +60.11% |
| 5-year return | — | +260.89% |
| P/E ratio (TTM) | — | 30.90 |
| Forward P/E | 69.06 | 24.54 |
| EPS (TTM) | $-2.74 | $9.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $268.09M |
| Revenue growth (YoY) | — | +60.40% |
| Net income (latest FY) | $-77.61M | $124.45M |
| Operating margin | — | 15.29% |
| Net margin | — | 46.42% |
| 52-week high | $200.00 | $326.63 |
| 52-week low | $76.50 | $175.89 |
| Distance from 52-week high | -21.96% | -10.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +46.65% | +17.39% |
| Average volume | 182.25K | 261.98K |
| Shares outstanding | 40.27M | 19.94M |
| Employees | 41 | 47 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BLTE has outperformed LGND by 41.5 percentage points over the past year.
About Belite Bio
BLTE stock →Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 41 employees
About Ligand Pharmaceuticals
LGND stock →Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 47 employees
BLTE vs LGND FAQ
Which is bigger, Belite Bio or Ligand Pharmaceuticals?
Belite Bio (BLTE) is larger, with a market capitalization of $6.29B compared with $5.85B for Ligand Pharmaceuticals (LGND).
Which stock has performed better over the past year, BLTE or LGND?
BLTE returned +101.65% over the past 12 months, compared with +60.11% for LGND (price return, excluding dividends). Past performance does not predict future results.
Are Belite Bio and Ligand Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.